Safety and Efficacy of 50 mg NYX-783 QD vs. Placebo in PTSD
NCT ID: NCT05181995
Last Updated: 2023-04-07
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
TERMINATED
PHASE2/PHASE3
121 participants
INTERVENTIONAL
2021-12-13
2023-03-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Safety and Efficacy of NYX-783 in Subjects With Post-Traumatic Stress Disorder
NCT04044664
A 40-week Study to Evaluate TNX-102 SL 5.6 mg Taken Daily at Bedtime in Patients With PTSD
NCT03508700
A Study of Flexible Dose Brexpiprazole as Monotherapy or Combination Therapy in the Treatment of Adults With Post-traumatic Stress Disorder (PTSD)
NCT03033069
A Phase 3 Study to Evaluate the Efficacy and Safety of TNX-102 SL in Participants With PTSD
NCT03841773
Proof-of-concept Study to Assess the Efficacy and Safety of SRX246 in Adults With PTSD
NCT02733614
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
50 mg NYX-783 QD
50 mg NYX-783 QD
NYX-783
NYX-783
Placebo
Placebo QD
Placebo
Placebo for 50 mg NYX-783
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
NYX-783
NYX-783
Placebo
Placebo for 50 mg NYX-783
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Stable allowed medications with no planned changes from 30 days prior to screening through study participation
* Willing to use highly effective birth control
* Willing to comply with protocol visits and procedures
Exclusion Criteria
* Other psychiatric disorders (based on SCID-5-CT) or neurodegenerative disorders
* Substance use disorder or alcohol use disorder within 6 months prior to screening
* Psychotherapy or cognitive based therapy within 30 days prior to screening
* Use of investigational drug within 30 days prior to screening
* Prior participation in study of NYX-783, NYX-2925 or NYX-458.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Worldwide Clinical Trials
OTHER
Aptinyx
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Aptinyx Clinical Site
Tuscaloosa, Alabama, United States
Aptinyx Clinical Site
Phoenix, Arizona, United States
Aptinyx Clinical Site
Bentonville, Arkansas, United States
Aptinyx Clinical Site
Bellflower, California, United States
Aptinyx Clinical Site
Glendale, California, United States
Aptinyx Clinical Site
La Jolla, California, United States
Aptinyx Clinical Site
Oceanside, California, United States
Aptinyx Clinical Site
Riverside, California, United States
Aptinyx Clinical Site
Santa Ana, California, United States
Aptinyx Clinical Site
Temecula, California, United States
Aptinyx Clinical Site
Torrance, California, United States
Aptinyx Clinical Site
Colorado Springs, Colorado, United States
Aptinyx Clinical Site
Denver, Colorado, United States
Aptinyx Clinical Site
Hialeah, Florida, United States
Aptinyx Clinical Site
Hollywood, Florida, United States
Aptinyx Clinical Site
Jacksonville, Florida, United States
Aptinyx Clinical Site
Jupiter, Florida, United States
Aptinyx Clinical Site
Miami, Florida, United States
Aptinyx Clinical Site
Miami, Florida, United States
Aptinyx Clinical Site
Miami Lakes, Florida, United States
Aptinyx Clinical Site
Okeechobee, Florida, United States
Aptinyx Clinical Site
Orlando, Florida, United States
Aptinyx Clinical Site
Atlanta, Georgia, United States
Aptinyx Clinical Site
Boston, Massachusetts, United States
Aptinyx Clinical Site
Las Vegas, Nevada, United States
Aptinyx Clinical Site
Albuquerque, New Mexico, United States
Aptinyx Clinical Site
New York, New York, United States
Aptinyx Clinical Site
Cincinnati, Ohio, United States
Aptinyx Clinical Site
Dayton, Ohio, United States
Aptinyx Clinical Site
Kettering, Ohio, United States
Aptinyx Clinical Site
North Canton, Ohio, United States
Aptinyx Clinical Site
Media, Pennsylvania, United States
Aptinyx Clinical Site
Memphis, Tennessee, United States
Aptinyx Clinical Site
Austin, Texas, United States
Aptinyx Clinical Site
Fort Worth, Texas, United States
Aptinyx Clinical Site
Houston, Texas, United States
Aptinyx Clinical Site
Plano, Texas, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
NYX-783-2009
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.